Cefiderocol

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bloodstream Infections

Conditions

Bloodstream Infections

Trial Timeline

Oct 28, 2019 → Jan 29, 2024

NCT ID

NCT03869437

About Cefiderocol

Cefiderocol is a phase 2 stage product being developed by Shionogi for Bloodstream Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03869437. Target conditions include Bloodstream Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03780140	Pre-clinical	Completed	—	—	Bacterial Infections
NCT07465432	Approved	Recruiting	Feb 16, 2026	Feb 28, 2027	Drug Clearance After Severe Burn Injury
NCT05789199	Pre-clinical	Completed	Jul 31, 2022	Jun 16, 2023	Gram-Negative Infection
NCT05373615	Phase 1	Completed	Jul 25, 2022	Nov 20, 2024	Pharmacokinetics
NCT05314764	Approved	Completed	Jun 1, 2022	Dec 11, 2024	Cystic Fibrosis
NCT04995835	Phase 1	Completed	Jul 16, 2021	Sep 1, 2024	Sepsis
NCT03869437	Phase 2	Completed	Oct 28, 2019	Jan 29, 2024	Bloodstream Infections

Competing Products

1 competing product in Bloodstream Infections

See all competitors

Product	Company	Stage	Hype Score
Daptomycin	Merck	Phase 2	52

Other Products from Shionogi

Naldemedine + PlaceboApproved

Rosuvastatin + HMG CoA inhibitorApproved

StatinApproved

CefiderocolApproved

Duloxetine + Pregabalin + PlaceboApproved